Biofrontera Inc. (NASDAQ:BFRI – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 467,400 shares, a growth of 17.3% from the December 15th total of 398,500 shares. Based on an average daily trading volume, of 107,900 shares, the short-interest ratio is presently 4.3 days. Approximately 3.7% of the company's stock are short sold.
Institutional Trading of Biofrontera
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp purchased a new stake in shares of Biofrontera during the second quarter worth about $39,000. State Street Corp grew its holdings in Biofrontera by 55.8% in the second quarter. State Street Corp now owns 22,900 shares of the company's stock valued at $43,000 after purchasing an additional 8,200 shares during the period. XTX Topco Ltd purchased a new stake in Biofrontera in the first quarter valued at approximately $48,000. BlackRock Inc. grew its holdings in Biofrontera by 894.0% in the first quarter. BlackRock Inc. now owns 100,505 shares of the company's stock valued at $335,000 after purchasing an additional 90,394 shares during the period. Finally, Bard Associates Inc. grew its holdings in Biofrontera by 5.4% in the second quarter. Bard Associates Inc. now owns 259,275 shares of the company's stock valued at $482,000 after purchasing an additional 13,200 shares during the period. Institutional investors and hedge funds own 6.84% of the company's stock.
Get
Biofrontera alerts:
Biofrontera Stock Performance
BFRI stock opened at $0.91 on Friday. The company's 50 day moving average price is $0.95 and its 200 day moving average price is $1.16. Biofrontera has a fifty-two week low of $0.75 and a fifty-two week high of $6.12. The firm has a market capitalization of $24.39 million, a price-to-earnings ratio of -0.81 and a beta of 1.12.
Biofrontera (NASDAQ:BFRI – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09. Biofrontera had a negative net
margin of 44.62% and a negative return on equity of 113.65%. The firm had revenue of $4.32 million for the quarter, compared to analyst estimates of $4.32 million. Equities analysts forecast that Biofrontera will post -0.98 EPS for the current fiscal year.
Biofrontera Company Profile
(Get Rating)
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Featured Stories
- Get a free copy of the StockNews.com research report on Biofrontera (BFRI)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
